Abstract
[Autom. eng. transl.] Within the HTA trial of Advate, octocog alfa, third generation recombinant factor VIII for the treatment and prophylaxis of bleeding episodes in patients with haemophilia A, the ethical aspects are analyzed in the light of efficacy and safety data, quality of life, economic impact of the disease.
| Translated title of the contribution | [Autom. eng. transl.] Advate HTA for treatment and prophylaxis in hemophilia A: ethical considerations |
|---|---|
| Original language | Italian |
| Pages (from-to) | 89-93 |
| Number of pages | 5 |
| Journal | Italian Journal of Public Health |
| Volume | 2011, vol. 8 |
| Publication status | Published - 2011 |
Keywords
- Advate
- Emofilia
- HTA
- etica